PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|November 9, 2005
Warning Letter: Diversified Manufacturing
Author(s)Pharmaceutical Technology Editors
This week, the US Food and Drug Administration posted an Oct. 20 Warning Letter (http://www.fda.gov/foi/warning_letters/g5567d.htm) sent by its Minneapolis, MN district office to Diversified Manufacturing Corporation (Newport, MN).
Advertisement
This week, the US Food and Drug Administration posted an Oct. 20 Warning Letter (
The two-page letter cited shortcomings in the company's manufacture of over-the-counter human drugs, including cited failures to validate equipment cleaning and maintain cleaning and maintenance records, especially for mixing vessels used for multiple products. The agency complained that the company did not have quality laboratory confirmation of conformance to specifications before the drug was released. The agency also found failures to investigate out of specification products.
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
In commercial tablet or capsule operations, validation helps protect the site’s ability to produce, release, and supply product without repeated disruption. This article discusses validation as a technical control system that supports manufacturing continuity.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Silvia Forroova, director of Partnerships & Sustainability at CPHI, and founder of the CPHI Sustainability Collective, provides a preview of the new Sustainability Summit at CPHI Milan 2026.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Lessons For AI Governance in Quality Systems
5